The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
What is the optimal treatment strategy of salvage line treatment after progression on anti-epidermal growth factor receptor monoclonal antibody in patients with tissue RAS/BRAF wild-type metastatic colorectal cancer?
 
Emiko Tange
No Relationships to Disclose
 
Hiroki Osumi
No Relationships to Disclose
 
Keitaro Shimozaki
No Relationships to Disclose
 
Koichiro Yoshino
No Relationships to Disclose
 
Mikako Tamba
No Relationships to Disclose
 
Shohei Udagawa
No Relationships to Disclose
 
Shota Fukuoka
No Relationships to Disclose
 
Mariko Ogura
No Relationships to Disclose
 
Takeru Wakatsuki
No Relationships to Disclose
 
Akira Ooki
Honoraria - Astellas Pharma; Bristol Myers Squibb Foundation; Daiichi Sankyo; Ono Pharmaceutical
 
Keisho Chin
No Relationships to Disclose
 
Kensei Yamaguchi
No Relationships to Disclose
 
Eiji Shinozaki
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha